Form 4: SOPHIA GENETICS SA: Insider Sells Shares for Tax Withholding

Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA, sold 5,285 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Abhimanyu Verma, Chief Technology Officer at SOPHiA GENETICS SA, reported a sale of 5,285 ordinary shares on July 6, 2026.
• The sale was conducted to satisfy tax withholding obligations stemming from the vesting of restricted stock units on July 2 and July 3, 2026.
• These transactions were executed under a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary.
• The shares were sold at a weighted average price of $5.1007, with individual sales ranging from $4.97 to $5.41.
• Following the transaction, Verma beneficially owns 192,171 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can be a negative signal, the clear explanation of tax withholding and the use of a Rule 10b5-1 plan mitigate significant concern.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, which is designed to comply with insider trading regulations and demonstrates adherence to proper corporate governance procedures.
• The sale was for tax withholding purposes, a common and expected event related to equity compensation, rather than a discretionary divestment of shares.

Negatives

• A portion of the insider's holdings was sold, which could be perceived negatively by the market, although the reason is for tax obligations.
• The sale represents a reduction in direct beneficial ownership by a key executive.

Risks

• While the sale is under a 10b5-1 plan for tax withholding, any significant insider selling can sometimes be misinterpreted by the market, potentially impacting short-term stock sentiment.
• The company's reliance on equity compensation, which leads to these tax withholding sales, could be a factor in future cash flow management if not properly planned.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it pertains to a past transaction.

Management Comments

• The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, particularly those related to tax withholding under Rule 10b5-1 plans, are common in the biotechnology and healthcare technology sectors where equity-based compensation is prevalent. These filings provide transparency into executive financial decisions.

Stakeholder Impact

• Shareholders: May view insider selling with caution, though the explanation for tax withholding under a 10b5-1 plan is a mitigating factor.
• Employees: The transaction highlights the use of equity compensation and its associated tax implications for executives.
• Management: Demonstrates adherence to regulatory requirements for reporting insider transactions.

Next Steps

• The reporting person may be required to provide further information upon written request from the SEC, the issuer, or any security holder.
• Continued monitoring of insider transactions for any further sales or purchases by Abhimanyu Verma or other executives.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Abhimanyu Verma, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership, Executive Compensation